Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: Assessing their impact on organ transplantation

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 676-682

  Patel, Gopi ^a   Perez, Federico ^a,b,c   Bonomo, Robert A ^b,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acinetobacter baumannii; carbapenem resistant; Klebsiella pneumoniae carbapenemase; multidrug resistant; organ transplant

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CALCINEURIN INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; PENICILLIN DERIVATIVE; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG ACTIVITY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; MOLECULAR EPIDEMIOLOGY; MULTIDRUG RESISTANCE; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MINOCYCLINE; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 78649641865     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283404373     Document Type: Review

References (101)

1. Singh N, Wagener M, Obman A, et al. Bacteremias in liver transplant recipients: shift toward Gram-negative bacteria as predominant pathogens. Liver Transplant 2004; 10:844-849.
2. Linares L,Garćia-Goez JF, Cervera C, et al. Earlybacteremiaaftersolid organ transplantation. Transplant Proc 2009; 41:2262-2264.
3. Rodriguez C, Munoz P, Rodriguez-Creixems M, et al. Bloodstream infections among heart transplant recipients. Transplantation 2006; 81:384-391.
4. Bert F, Larroque B, Paugam-Burtz C, et al. Microbial epidemiology and outcomeof bloodstream infections in livertransplant recipients:an analysis of 259 episodes. Liver Transplant 2010; 16:393-401.
5. Singh N, Gayowski T, Rihs J, et al. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of anti-microbial susceptibility patterns. Liver Transplant 2001; 7:22-26.
6. Linares L, Cervera C, Cofan F, et al. Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing Gram-negative rods in renal transplantation. Am J Transplant 2008; 8:1000-1005.
7. Shi SH, Kong HS, Xu J, et al. Multidrug resistant Gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11:405-412.
8. Van Delden C, Blumberg EA. Multidrug resistant Gram-negative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S27-S34.
9. Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative or-ganisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570.
10. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in Gram-negative bacilli. Clin Infect Dis 2007; 45:1179-1181.
11. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46:1121-1122.
12. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carba-penem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-1033.
13. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007; 60:1124-1130.
14. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-2212.
15. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of postacute care facilities on dissemination. J Antimicrob Chemother 2010. doi: 10.1093/jac/dkq191.
16. Singh N, Paterson DL, Chang FY, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant Gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000; 30:322-327.
17. Gearhart M, Martin J, Rudich S, et al. Consequences ofvancomycin- resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transplant 2005; 19:711-716.
18. McNeil SA, Malani PN, Chenoweth CE, et al. Vancomycin-resistant enter-ococcal colonization and infection in liver transplant candidates and reci-pients: a prospective surveillance study. Clin Infect Dis 2006; 42:195-203.
19. Munoz P. Multiply resistant Gram-positive bacteria: vancomycin-resistant Enterococcus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S50-S56.
20. Garzoni C. Multiply resistant Gram-positive bacteria methicillin- resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S41-S49.
21. Bert F, Bellier C, Lassel L, et al. Risk factors for Staphylococcus aureus infection in livertransplant recipients. Liver Transpl 2005; 11:1093-1099.
22. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing ß-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneu-moniae. Antimicrob Agents Chemother 2001; 45:1151-1161.
23. Souli M, Galani I, Antoniadou A, Papadomichelakis E, et al. An outbreak of infection due to beta-lactamase Klebsiella pneumoniae carbapenemase 2-producing Kpneumoniaeina Greek University Hospital: molecularcharacter- ization, epidemiology, and outcomes. Clin Infect Dis 2010; 50:364-373.
24. Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026-3029.
25. Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumo-niae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793-4799.
26. Landman D, Bratu S, Kochar S, et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacterbaumanniiand Klebsiella pneumoniae in Brooklyn, NY. J Antimicrob Chemother 2007; 60:78-82.
27. Srinivasan A, Patel JB. Commentary: Klebsiella pneumoniae carbapene-mase-producing organisms: an ounceof prevention really isworth apound of cure. Infect Control Hosp Epidemiol 2008; 29:1107-1109.
28. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: an-nual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
29. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunc-tive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-1106.
30. Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010; 67:180-184.
31. Woodford N, Dallow JW, Hill RL, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007; 29:456-459.
32. Lopez JA, Correa A, Navon-Venezia S, et al. Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain. Clin Microbiol Infect2010.doi: 10.1111/j.1469-0691.2010.03209.x.
33. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006; 43:e26-e28.
34. Bennett JW, Herrera ML, Lewis JS II, et al. KPC-2-producing Enterobacter cloacae and Pseudomonas putida coinfection in a liver transplant recipient. Antimicrob Agents Chemother 2009; 53:292-294.
35. Mathers AJ, Cox HL, Bonatti H, Kitchel B, et al. Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009; 11:257-265.
36. Sidjabat HE, Silveira FP, Potoski BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009; 49:1736-1738.
37. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228-236.
38. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneu-moniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119-1125.
39. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006; 38:1081-1084.
40. Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbape-nemases: a tale of strains, plasmids, and transposons. Clin Infect Dis 2009; 49:1739-1741.
41. Rice LB, Carias LL, Hutton RA, et al. The KQ element, a complex genetic region conferring transferable resistancetocarbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Che-mother 2008; 52:3427-3429.
42. Endimiani A, Carias LL, Hujer AM, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother 2008; 52:2680-2682.
43. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53:3365-3370.
44. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723-2725.
45. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Kleb-siella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006; 12:1209-1213.
46. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-1435.
47. McGettigan SE, Andreacchio K, Edelstein PH. Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapene-mases. J Clin Microbiol 2009; 47:785-786.
48. Tsakris A, Poulou A, Themeli-Digalaki K, et al. Useof boronicacid diskteststo detect extended-spectrum β-lactamases in KPC carbapenemase-possessing Enterobacteriaceae clinical isolates. J Clin Microbiol 2009; 47:3420-3426.
49. Tsakris A, Kristo I, Poulou A, et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiellapneumoniae isolates in the clinical laboratory. J Clin Microbiol 2009; 47:362-367.
50. Centers for Disease Control and Prevention. Guidance for control of infec-tions with carbapenem-resistant or carbapenemase-producing Enterobac-teriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256-260.
51. Samra Z, Bahar J, Madar-Shapiro L, et al. Evaluation of CHROMagar KPCfor rapid detection ofcarbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2008; 46:3110-3111.
52. Carrer A, Fortineau N, Nordmann P. Use of ChromID extended-spectrum beta-lactamase mediumfordetecting carbapenemase-producing Enterobac-teriaceae. J Clin Microbiol 2010; 48:1913-1914.
53. National Nosocomial Infections Surveillance (NNIS) System Report, data summaryfromJanuary 1992 through June 2004, issued October 2004.Am J Infect Control. 2004; 32:470-485.
54. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24:284-295.
55. Trottier V, Namias N, Pust DG, et al. Outcomes of Acinetobacterbaumannii infection in critically ill surgical patients. Surg Infect 2007; 8:437-443. (Pubitemid 47493521)
56. Sopirala MM, Pope-Harman A, Nunley DR, et al. Multidrug-resistant Acine-tobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant 2008; 27:804-807.
57. Reddy P, Zembower TR, Ison MG, et al. Carbapenem-resistant Acinetobacterbaumanniiinfections afterorgan transplantation. Transpl Infect Dis 2010; 12:87-93.
58. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacterbaumanniiventilator-associated pneu-monia. J Infect 2008; 56:432-436.
59. Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369-1375.
60. Reddy T, Chopra T, Marchaim D, et al. Trends in antimicrobial resistance of Acinetobacterbaumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother 2010; 54:2235-2238.
61. Doi Y, Husain S, Potoski BA, et al. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15:980-982.
62. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacterbaumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826-836.
63. Perez F, Hujer AM, Hujer KM, et al. Global challenge of multidrug-resistant Acinetobacterbaumannii. Antimicrob Agents Chemother 2007; 51:3471-3484.
64. Robledo IE, Aquino EE, Sante MI, et al. Detection of KPC in Acinetobacterspp. in Puerto Rico. Antimicrob Agents Chemother 2010; 54:1354-1357.
65. Swenson JM, Killgore GE, Tenover FC. Antimicrobial susceptibility testing of Acinetobacterspp. by NCCLS broth microdilution and diskdiffusion meth-ods. J Clin Microbiol 2004; 42:5102-5108.
66. Akers KS, Chaney C, Barsoumian A, et al. Aminoglycoside resistance and susceptibilitytesting errors inAcinetobacterbaumannii-calcoaceticus complex. J Clin Microbiol 2010; 48:1132-1138.
67. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxinsforthe manage-ment of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-1341.
68. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21:449-465.
69. Zavascki AP, Goldani Z, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47:1298-1304.
70. Urban C, Mariano N,Rahal JJ. Invitrodouble and triplebactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Aci-netobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother 2010; 54:2732-2734.
71. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and otheragents. JAntimicrob Chemother 2005; 56:128-132.
72. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43 (Suppl 2):S89-S94.
73. Falagas M, Kasiakou S. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Critical Care 2006; 10:R27.
74. Wahby K, Chopra T, Chandrasekar P. Intravenous and inhalational colistin-induced respiratoryfailure. Clin Infect Dis 2010; 50:e38-e40.
75. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infec-tions. Clin Infect Dis 2005; 41 (Suppl 5):S303-S314.
76. Gordon NC, Wareham DW. A review of clinical and microbiological out-comes following treatment of infections involving multidrug-resistant Acine-tobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-780.
77. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Aci-netobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45-55.
78. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59:128-131.
79. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility inAcinetobacterbaumannii. Antimicrob Agents Chemother 2007; 51:2065-2069.
80. Daly MW, Riddle DJ, Ledeboer NA, et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27:1052-1057.
81. Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570.
82. Woodford N, Hill RL, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and-resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 2007; 59:582-583.
83. Cunha BA, McDermott B, Nausheen S. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enter-obacter aerogenes nosocomial urinary tract infection. J Chemother 2007; 19:753-754.
84. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: areportof 2 casesand abriefreviewoftheliterature. Clin Infect Dis 2009; 49:271-274.
85. Falagas ME, Bliziotis IA, Kasiakou SK, et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5:24.
86. Matthew EF, Petros IR, Dimitrios KM, et al. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii in-fections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008; 32:450-454.
87. Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009; 47:1611-1612.
88. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27:439-443.
89. Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiellapneumoniae isolates, including those nonsus-ceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010; 54:526-529.
90. Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with β-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother 2009; 53:3599-3601.
91. Stachyra T, Levasseur P, Pechereau M-C, et al. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enter-obacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009; 64:326-329.
92. Papp-Wallace KM, Bethel CR, Distler AM, et al. Inhibitor resistance in the KPC-2 beta-lactamase, apreeminent propertyofthisclassAbeta-lactamase. Antimicrob Agents Chemother 2010; 54:890-897.
93. Endimiani A, Bethel C, Choudhary Y, Bonomo RA. In vitro activity of penem-1 in combination with beta-lactams against blaKPC-possessing Klebsiella pneumoniaeisolates. Antimicrob Agents Chemother 2010; 54:1650-1651.
94. Endimiani A, Hujer KM, Hujer AM, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009; 53:4504-4507.
95. Vaara M, Siikanen O, Apajalahti J, et al. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia colito the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J Antimicrob Chemother 2010; 65:942-945.
96. Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8:1737-1743.
97. Lease ED, Zaas DW. Complex bacterial infections pre and posttransplant. Semin Respir Crit Care Med 2010; 31:234-242.
98. Calfee D, Jenkins SG. Use of active surveillance cultures to detect asympto-matic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 2008; 29: 966-968.
99. Gill J, Madhira BR, Gjertson D, et al.Transplanttourism in the United States: a single-center experience. Clin J Am Soc Nephrol 2008; 3:1820-1828.
100. Merion RM, Barnes AD, Lin M, et al. Transplants in foreign countries among patients removed from the US transplant waiting list. Am J Transplant 2008; 8:988-996.
101. Reed AI, Merion RM, Roberts JP, et al. The Declaration of Istanbul: reviewand commentary by the American Society of Transplant Surgeons Ethics Com-mittee and Executive Committee. Am J Transplant 2009; 9:2466-2469.